OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	489
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	213
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	175
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	172
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	166
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	165
Commentary on oncolytic viruses: past, present, and future	148
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	145
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	137
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	136
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	132
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	129
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	129
Correction: Two roads for oncolytic immunotherapy development	126
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	126
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	126
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	119
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	118
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	115
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	115
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	114
Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	113
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	110
Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity	110
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	106

Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	102
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	101
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	99
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	98
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphoma	98
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images	96
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	96
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes	96
Biomarkers for response to TIL therapy: a comprehensive review	94
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	91
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	90
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	89
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	89
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	88
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	87
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	86
T-cell tolerant fraction as a predictor of immune-related adverse events	86
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	85
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	84
iRECIST and atypical patterns of response to immuno-oncology drugs	82
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	82
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	82
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	81
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release	80
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	79
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	79
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	79
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	79
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	79
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	78
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	78
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	76
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	74
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	73
Modulating lipid metabolism improves tumor immunotherapy	73
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	73
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	72
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	71
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	69
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	69
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	68
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	67
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	67